Skip to main content


Accurate anatomic subtyping, optimal diagnostic imaging, and molecular classification are among the most pressing needs with NETs. Read More ›

The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery. Read More ›

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity. Read More ›

Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome. Read More ›

An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials. Read More ›